Skip to main content
. 2011 Dec 29;99(1):167–184. doi: 10.1093/biomet/asr062

Table 2.

Model estimates for the panitumumab data

Parameter EST SE P Parameter EST SE P
TD Model TU Model
Treatment −0.464 3.47 0.182 Treatment −1.144 1.18 <0.001
Age 0.023 0.15 0.124 Age −0.015 0.05 0.004
bECOG −0.589 2.99 0.048 bECOG −0.805 1.74 <0.001
Rectal −0.028 3.20 0.929 Rectal −0.018 1.10 0.871
Male −0.288 3.05 0.345 Male −0.054 1.09 0.622
CenEastEU −0.188 6.27 0.764 CenEastEU 0.194 2.50 0.439
WesternEU 0.181 3.99 0.650 WesternEU −0.068 1.60 0.672
TG Model U Model
Treatment −0.784 2.14 <0.001 Intercept 1.366 9.72 0.160
V*(1-Treatment) −1.383 2.09 <0.001 Treatment −1.070 3.19 <0.001
Prog Time −0.003 0.01 0.039 Age −0.008 0.14 0.546
PR Age −0.004 0.05 0.450 bECOG 1.905 3.34 <0.001
BTR PR −0.226 3.45 0.512 Rectal 0.314 3.31 0.342
BTR SD −0.180 1.74 0.302 Male −0.303 3.21 0.346
bECOG −0.268 1.96 0.173 CenEastEU 0.078 6.23 0.901
LECOG −1.035 1.48 <0.001 WesternEU 0.346 4.12 0.400
AE 0.295 1.16 0.011

EST, parameter estimates; SD(×10), standard error of the estimates; P, p-values; bECOG, baseline electrocorticography; CenEastEU, central Europe; WesternEU, western Europe; Prog Time, progression time; PR, partial response; BTR, best tumour response; SD, stable disease; LECOG, last electrocorticography; AE, adverse event.